AstraZeneca plc (AZN) PT Set at GBX 5,333 by Sanford C. Bernstein
AstraZeneca plc (LON:AZN) has been given a GBX 5,333 ($65.00) price target by stock analysts at Sanford C. Bernstein in a research note issued on Wednesday. The firm currently has a a “neutral” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price target indicates a potential upside of 6.62% from the stock’s previous close.
Several other equities research analysts have also recently issued reports on AZN. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,800 ($70.69) target price on shares of AstraZeneca plc in a report on Friday, July 29th. Berenberg Bank set a GBX 5,550 ($67.64) target price on shares of AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday, August 25th. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($48.75) target price on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Wednesday, August 10th. Finally, Bryan, Garnier & Co restated a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 4,966.24 ($60.53).
AstraZeneca plc (LON:AZN) traded down 1.22% during midday trading on Wednesday, hitting GBX 4941.00. 856,451 shares of the company were exchanged. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The stock’s market capitalization is GBX 62.50 billion. The stock has a 50 day moving average of GBX 4,996.12 and a 200-day moving average of GBX 4,492.93.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/astrazeneca-plc-azn-pt-set-at-gbx-5333-by-sanford-c-bernstein-2.html
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.